Bridging integrator 1 (bin1) gene is a genetic determinant of Alzheimer's disease (AD) and has been reported to modulate Alzheimer's pathogenesis through pathway(s) involving Tau. The functional impact of Tau/BIN1 interaction as well as the molecular details of this interaction are still not fully resolved. As a consequence, how BIN1 through its interaction with Tau affects AD risk is also still not determined. To progress in this understanding, interaction of Tau with two BIN1 isoforms was investigated using Nuclear Magnetic Resonance spectroscopy. N spectra showed that the C-terminal SH3 domain of BIN1 isoform 1 (BIN1Iso1) is not mobile in solution but locked with the core of the protein. In contrast, the SH3 domain of BIN1 isoform 9 (BIN1Iso9) behaves as an independent mobile domain. This reveals an equilibrium between close and open conformations for the SH3 domain. Interestingly, a 334-376 peptide from the clathrin and AP-2-binding domain (CLAP) domain of BIN1Iso1, which contains a SH3-binding site, is able to compete with BIN1-SH3 intramolecular interaction. For both BIN1 isoforms, the SH3 domain can interact with Tau(210-240) sequence. Tau(210-240) peptide can indeed displace the intramolecular interaction of the BIN1-SH3 of BIN1Iso1 and form a complex with the released domain. The measured K d were in agreement with a stronger affinity of Tau peptide. Both CLAP and Tau peptides occupied the same surface on the BIN1-SH3 domain, showing that their interaction is mutually exclusive. These results emphasize an additional level of complexity in the regulation of the interaction between BIN1 and Tau dependent of the BIN1 isoforms.
Introduction
Genome-wide association studies identified bridging integrator-1 (bin1) as a susceptibility gene for Alzheimer's disease (AD) [1] [2] [3] and meta-analysis showed that bin1 is the second highest genetic risk factor of AD, after the ApoE gene [4] .
There are several isoforms of BIN1, also called amphiphysin 2, resulting from alternative splicing, which have specific tissue distribution, cellular localization and functions. BIN1 protein isoforms 1-7 are expressed in the brain, isoform 8 in the muscle and isoform 9 and 10 are ubiquitous. All BIN1 isoforms contain a N-terminal Bin/amphiphysin/Rvs (BAR) domain that binds to membranes in a dimer conformation and functions in membrane remodelling [5] (Fig. 1A) . The BAR domain composition itself differs between the isoforms due to differential splicing of exon7, the neuronal isoforms having an insertion of 31 amino acid residues [6] . A C-terminal Src-homology-3 (SH3) domain (BIN1-SH3) that mediates interactions of BIN1 with several partners such as dynamin, is also found in all BIN1 isoforms. Finally, BIN1 isoforms also have a Myc-binding domain (MBD) that binds cMyc transcription factor and regulates its function [7] . BIN1 isoforms otherwise differ by their domain composition. A clathrin and AP-2-binding domain (CLAP domain) is only present in the brain-specific BIN1 isoforms and is involved in endocytosis [8, 9] , while a phosphoinositide (PI)-binding motif is found in a muscle-specific isoform and ensures localization to membrane [10] .
How BIN1 protein contributes to the increased risk to develop AD is currently unknown. BIN1 has been described to directly interact with the Tau protein [11, 12] , using NMR spectroscopy with recombinant proteins, in vitro glutathion S-transferase (GST) pulldown from HEK293 lysates, polymerase ligation assays in primary neuronal culture [12] , as well as reciprocal coimmunoprecipitations from wild-type mouse brain homogenates, which confirm interaction at the physiological level [11] . These data support the hypothesis that BIN1 might modulate the pathophysiological process involving Tau, a leading cause of neurodegeneration [13] [14] [15] . A functional variant modulating BIN1 expression is associated with neurofibrillary tangles, which are intraneuronal aggregates formed by abnormally phosphorylated Tau proteins [11] . In addition, in a Drosophila melanogaster model overexpressing Tau, bin1 homologue Amph mediates Tau toxicity [11, 16] , and an increase in bin1 expression is observed in AD [11] . However, this global pattern of expression may differ between the BIN1 isoforms: at the protein level in the brain of AD case, a decrease in BIN1Iso1 (the largest BIN1 isoform) was reported, whereas an increase in BIN1Iso9 (the shortest) was measured [17] . In line with Tau, it has been suggested that the BIN1-Tau complex could be at the interface between the actin and microtubule network and that its deregulation may impact neuronal function [12] . It has also been proposed that BIN1 may control Tau aggregate entry into the cell through clathrin-dependent endocytic influx. This would lead to the propagation of Tau pathology from neuron to neuron after aggregates of Tau permeabilize the endosome membrane [18] . Beyond Tau, since BIN1 has been observed to be mainly expressed in oligodendrocytes, this led to propose that BIN1 may deregulate myelination [19, 20] . Finally, BIN1 has been reported to increase cellular BACE1 levels through impaired endosomal trafficking and reduced BACE1 lysosomal degradation, resulting in increased Ab production [21] . In conclusion, since the physiological and pathological roles of BIN1 have to be better dissected, we decided to continue our efforts in order to better understand how BIN1 and Tau interact at the molecular level. We have previously shown direct interaction of the SH3 domain of BIN1 with the proline-rich domain of Tau (PRD, Tau [165-245]) [12] . The interaction motif within Tau PRD was narrowed down to a sequence located between amino acid residues 210-240 [12] . We have additionally shown, both in vitro and in primary neuronal cell culture, that Tau phosphorylation affects the interaction of Tau with BIN1 [12] . In this report we went further and we addressed the isoform-specific regulation of the interaction of BIN1 with Tau. We chose in this study to compare the BIN1 isoform1 (BIN1Iso1) and BIN1 isoform9 (BIN1Iso9) isoforms (Fig. 1A) , representing, respectively, the longest and shortest isoforms, which are the major isoforms present in brain tissues and show differential modification of protein level in AD [17] , suggesting distinct functions.
Results
BIN1-SH3 domain is mobile in BIN1 isoform 9 but has a shifted equilibrium towards rigid incorporation in isoform 1
We previously identified the interaction region of Tau with the isolated SH3-domain of BIN1 (BIN1-SH3) [12] . To further understand how this interaction is regulated, the interaction of the full neuronal (BIN1Iso1) and ubiquitous (BIN1Iso9) BIN1 protein isoforms, both containing BIN1-SH3 domain at their C termini, were compared. As a first step, 1 H-15 N HSQC 2D spectrum of each isoform, BIN1Iso9 and BIN1Iso1, were recorded. The large molecular weight of BIN1 (BIN1Iso9, 91.1 kDa, BIN1Iso1, 129 kDa homodimers) is expected to lead to a long overall rotational correlation time, fast relaxation and severe line broadening in the spectra. However, as it was previously demonstrated with large complexes, it might still be possible to detect sharp NMR signals from the more dynamic parts of these proteins [22] [23] [24] . In accordance, 1 H-15 N HSQC spectrum of BIN1Iso9 displays in the central part of the spectrum signal of low spectral dispersion typical of disordered regions of proteins, which are indeed expected to be dynamic. However, some additional well-dispersed peaks (Fig. 1B) , which are characteristic of folded domains, are also present in BIN1Iso9 2D spectrum. These welldispersed resonances overlaid quite well with those observed in the individual BIN1-SH3 domain 1 H-15 N HSQC spectrum (Fig. 1C) . This observation indicates that the BIN1-SH3 domain structure is unchanged and that the domain has significant mobility in the context of BIN1Iso9 protein. In contrast, the signals corresponding to the isolated BIN1-SH3 domain are barely detected in the 1 H- 15 N HSQC spectrum of BIN1Iso1 (Fig. 1D) , suggesting that the overall tumbling rate of the SH3 domain of BIN1Iso1 has the same order of magnitude as the one of the full BIN1Iso1. This domain is thus mainly rigidly incorporated, in an equilibrium shifted towards a close conformation, during the NMR acquisition time.
BIN1-SH3 domain is engaged in an intramolecular interaction in BIN1Iso1
Interactions of amphiphysin-related proteins are regulated by complex mechanisms, not yet fully understood. Previous reports showed in amphiphysin-related proteins that intramolecular interaction of a C-terminal SH3 domain is able to modulate interactions with membranes and/or molecular partners [25] [26] [27] [28] [29] [30] . A possible reason for the reduced mobility of BIN1-SH3 domain in the context of BIN1Iso1 could be its involvement in such an intramolecular interaction. Comparison of the SH3 domain mobility in BIN1Iso1 and BIN1Iso9 might suggest that the BAR domain is not responsible for the intramolecular interaction of the SH3 domain as both isoforms have a BAR domain and the SH3 domain remains mobile in the BIN1Iso9. However, there is a small difference between the BIN1Iso9 and BIN1Iso1 BAR corresponding to a 31-amino acid residue sequence encoded by exon7, present only in BIN1Iso1. SH3 domains are known to mediate protein-protein interactions through the recognition of proline-rich sequence motifs [31] [32] [33] [34] . The amino acid sequence corresponding to exon7 does not contain such a motif (Fig. 1A) . Firstly, to confirm that there is no possible intramolecular interaction between the BAR domain of BIN1Iso1 and the BIN1-SH3 domain, a 1 H-15 N HSQC spectrum of BIN1-SH3 domain was acquired in the presence of an excess of BAR domain ( Fig. 2A) . No significant CSP were observed, confirming that the BAR domain of BIN1I-so1 does not contain an SH3 binding site. Comparison of BIN1Iso1 and BIN1Iso9 domain organization (Fig. 1A ) also shows the exclusive presence of a CLAP-binding domain in BIN1Iso1. Additional sequence analysis indicates that the CLAP domain, encoded by exon13 [5] , contains a class I proline-rich motif between residues 336 and 342 [32] , a motif previously described to be able to interact with BIN1-SH3 [26] . To verify that the reduced mobility of BIN1-SH3 in BIN1Iso1 could be due to an intramolecular (Fig. 2C) , in agreement with a previous report [26] . In addition, a colinear chemical shift deviation was observed for resonances affected by the interaction of the BIN1-SH3 domain, either isolated or integrated in BIN1Iso1 protein, with the CLAP(334-376) peptide (Fig. 2D) . A colinear chemical shift deviation is expected for resonances in fast exchange between the SH3-free state and a similar SH3-bound state, showing that the BIN1-SH3 domain share the same binding interface for the CLAP(334-376) peptide as an isolated domain or in BIN1Iso1.
These results indicate that BIN1-SH3 domain binds to the proline-rich motif of CLAP(334-376) peptide and that this interaction is able to displace a competing intramolecular interaction, which is responsible for the immobilization of the BIN1-SH3 domain of BIN1Iso1.
BIN1-SH3 domain within both BIN1Iso1 and BIN1Iso9 interacts with Tau Proline-rich domain
Having shown that the BIN1-SH3 domain is engaged in an intramolecular interaction in BIN1Iso1, but not in BIN1Iso9, the molecular characterization of the interaction of BIN1 with Tau was pursued by verifying the capacity of Tau PRD to interact with BIN1-SH3, in the context of full BIN1 proteins. Signals from the BIN1-SH3 domain in the context of BIN1Iso9 are readily observable. Addition of Tau PRD to 15 N-BIN1Iso9 lead to chemical shift perturbations of the signals corresponding to BIN1-SH3, in the same manner as for the isolated domain (Fig. 3A,B) . In the case of BIN1Iso1, BIN1-SH3 domain is engaged in an intramolecular interaction, its corresponding resonances have weak intensities and are barely detected in the 2D spectrum (Fig. 1D) . Tau(210-240) and CLAP(334-376) peptides compete for BIN1-SH3 binding
To better understand the equilibrium between the intra-and intermolecular interactions of BIN1-SH3 domain of BIN1Iso1, the dissociation constants K d characterizing the interactions of Tau(210-240) and CLAP(334-376) peptides with BIN1-SH3 were measured (Fig. 4) . (Fig. 4A) . ITC experiments to measure binding affinities to CLAP(334-376) peptide did not allow fitting of the binding isotherm, as saturation could not be reached (Fig. 4C) . These data confirm the lower affinity of the CLAP(334-376) peptide compared to Tau(210-240) peptide. To evaluate the capacity of Tau(210-240) peptide to compete with CLAP(334-376) peptide for BIN1-SH3 binding, an excess of Tau(210-240) peptide (1 : 8 molar ratio) was added to 15 N-BIN1-SH3/CLAP(334-376) complex (1 : 8 molar ratio) and the resulting equilibrium was probed with a 1 H-15 N HSQC NMR experiment. The resulting spectrum matched the one of BIN1-SH3/Tau (210-240) complex (Fig. 4D) , indicating that at an equimolar concentration, Tau(210-240) peptide displaced the CLAP(334-376) peptide from its SH3-binding interface.
Tau(210-240) and CLAP(334-376) peptides share the same interaction surface on BIN1-SH3
To verify whether the CLAP peptide and the Tau PRD peptide shared the same binding site on BIN1-SH3 domain surface, chemical shift perturbation data were used. The profile of perturbations reported along BIN1-SH3 domain is similar with both peptides (Fig. 5A) . The extent of perturbations is smaller with the CLAP(334-376) peptide at comparable stoichiometry, which might be due to its lower affinity. Reporting the chemical shift perturbations resulting from the addition of Tau(210-240) peptide and CLAP(334-376) peptides on the surface of the NMR structure of BIN1-SH3 [26] allowed to visualize the binding regions (Fig. 5B) . Addition of the peptides affected mainly resonances corresponding to residues located in the canonical SH3-binding site, which is formed by the RT loop, the N-Src loop, and b-strands 4 and 5 (Fig. 5A ). Reporting these data on the SH3 domain surface highlighted a pocket previously described to accommodate proline-rich motifs, corresponding to the xP-binding pocket, which interacts with the PxxP motif, and the specificity zone, which binds sequences immediately N-or C-terminal to the PxxP motif of the ligand [34, 35] (Fig. 5B ). In conclusion, Tau(210-240) and CLAP(334-376) peptides shared a binding surface on BIN1-SH3 domain that corresponds to the prolinerich binding site of SH3 domains, and their binding is mutually exclusive.
Discussion
The interaction of BIN1 with Tau is potentially involved in the pathophysiological process of AD and studying its regulation is thus important to understand its specific contribution. We previously described a mechanism by which the interaction of BIN1 with Tau might be regulated in cells, as we observed that this interaction is decreased by specific Tau phosphorylations [12] . In this report, we described another level of complexity susceptible to control the BIN-Tau interaction which is dependent on the ubiquitous BIN1Iso9 and neuronal BIN1Iso1 isoforms. In the BIN1Iso1 2D spectra, signals from its SH3 domain are weak or not detected, even at the noise level, indicating that this domain does not behave as a small independent module. This behaviour is specific for the BIN1Iso1 isoform as signals of the SH3 of BIN1Iso9 are all detected with good relative intensity in its 2D spectrum, showing that it is rotating freely in solution, in an open conformation. Autoinhibition of BAR and F-BAR (Fer-CIP4 homology-BAR) containing proteins by intramolecular interaction of the BAR domain with a SH3 domain has already been described [25, 29, 30] . This is the case, for example, for the syndapin 1 and its F-BAR domain whose crystal structure shows autoinhibition by its SH3 domain [25] . The SH3 domain contacts a basic patch on charged concave surface of the syndapin 1 BAR domain dimers by its negatively charged side (RT-src loop), which is the side of the proline-rich binding groove. Of note, the BAR domain of BIN1 (present in all the BIN1 isoforms) does not contain the characteristic basic cluster that would allow docking of the SH3 domain by electrostatic interaction as observed in syndapin-1. Furthermore, the BAR domain of BIN1Iso9, which only differs by a 31-amino acid sequence encoded by exon7 from the BIN1Iso1 BAR domain (Fig. 1A) , does not restrain the mobility of the BIN1Iso9 SH3 domain (Fig. 1B) . Finally, the absence of CSP in a 2D spectrum of 15 N-SH3 domain in the presence of an excess of the BIN1Iso1 BAR domain ( Fig. 2A) confirms that the BAR domain is not responsible for an intramolecular interaction of the SH3 domain in BIN1Iso1. Another described site of intramolecular interaction of the BIN1-SH3 domain is the PI motif [28] , which is, however, absent from both BIN1Iso1 and BIN1Iso9 sequences. However, in line with the isoform-specific behaviour of the BIN1-SH3 domain, the CLAP domain containing an SH3-binding site, is only present in BIN1Iso1 (Fig. 1A) . We showed that a CLAP(334-376) peptide, containing this SH3-binding site, can displace the intramolecular interaction of BIN1-SH3 domain in BIN1Iso1. All together, we concluded that the C-terminal SH3 domain of BIN1Iso1 is involved in an equilibrium between an open and close conformation, the equilibrium being shifted towards the close conformation due mainly to intramolecular interaction with its CLAP domain.
We next investigated how the BIN1 isoforms interact with Tau. The interaction of BIN1-SH3 domain with Tau is the same as indicated by identical chemical shift perturbations in respective spectra whatever the type of constructs used (a full BIN1Iso9 isoform protein or an isolated SH3 domain, Fig. 3A,B) . This indicates that the binding surface of the domain (Fig. 5) is the same for the free BIN1-SH3 than for the linked one. For BIN1Iso1, the addition of Tau(210-240) peptide lead to the appearance of the bound SH3 signals in the spectrum, showing that in the presence of Tau, the intramolecular interaction was displaced and the equilibrium shifted towards an open state of BIN1Iso1 (Fig. 3C ). In addition, reproducing the competition with an isolated SH3 domain shows that the Tau peptide can replace the CLAP peptide in the binding pocket of the SH3 domain by simple equilibrium shift. Definition of the K d are in accordance since the affinity of the BIN1-SH3 domain for the Tau peptide is higher than for the CLAP peptide. Of note, although affinity is lower for the CLAP peptide, it is important to keep in mind that this affinity could be underestimated. Indeed, it might be higher in the context of the full protein if considering that the two domains are attached together. Nevertheless, we observed that in this context, Tau is still able to displace the intramolecular interaction (Fig. 3C ) in the same conditions that showed that Tau peptide can take the place of the CLAP peptide bound to the isolated BIN1-SH3 domain (Fig. 4D) . Mapping of the interaction site of both Tau and CLAP peptides additionally shows that the same proline-rich binding pocket is occupied on BIN1-SH3 surface. The binding of the CLAP or Tau peptides are thus mutually exclusive. Based on our data, the modulation of Tau/BIN1Iso1 interaction by the intramolecular immobilization of its SH3 domain showed that binding to Tau requires an equilibrium shift towards the intermolecular interaction. The intramolecular interaction thus provides a way to modulate the BIN1/Tau interaction and the availability of the CLAP domain to recruit its partners. The equilibrium shift might require a fine tuning of the available partners at a specific location in the neurons, restricting the interaction. In addition, specific phosphorylations of the Tau protein would consequently indirectly regulates CLAP domain interaction, by decreasing its capacity to interact with the BIN1-SH3 domain and thus decreasing the availability of the CLAP due to the intramolecular interaction. Knowing that Tau phosphorylation and localization are abnormal in AD, this finely regulated network of BIN1Iso1 interactions could in turn be affected. Even if other mechanisms are under discussion to explain the impact of the different BIN1 isoforms on the AD pathophysiological processes, for example, Tau pathology propagation modulated through BIN1-dependent endocytosis [18] , our study by revealing mechanistic insight of the Tau/Bin1 interaction dependent on specific BIN1 isoforms will contribute to a better understanding of their potential distinct roles in AD pathology. Of note, this would be of particular relevance since it was suggested a differential expression of these isoforms in the AD brain [17] .
Material and methods

Proteins and peptides
BIN1 isoform 1 (BIN1Iso1), BIN1 isoform 9 (BIN1Iso9), BIN1Iso1 BAR domain (amino acid residues 1-300 of BIN1Iso1), and BIN1SH3 domain (Amino acid residues 513-593 of BIN1Iso1) cDNA sequences were cloned into the pET-15b expression vector (Novagen, Merck, Darmstadt, Germany) between NdeI and XhoI restriction sites. cDNAs were synthetized with optimized codon composition for expression in bacteria (Genecust, Ellange, Luxembourg). The obtained expression vectors were transformed into Escherichia coli BL21 DE3 cells. Cells were grown at 37°C to an absorbance at 600 nm of 0.8 and induced with 1 mM IPTG for 3 h. These highly expressed proteins were purified using a nickel affinity chromatography column. For the BIN1-SH3 domain, the protein was incubated with thrombin protease at 22°C overnight, and then the cleaved protein was purified by a Superdex 75 size exclusion column using 50 mM sodium phosphate pH 7.3, 30 mM NaCl, 3 mM DTT as running buffer. BIN1Iso1 and BIN1Iso9 were loaded onto a Superdex 200 size exclusion column for further purification in 50 mM sodium phosphate pH 7.3 buffer, 30 mM NaCl and 3 mM DTT. All the purification steps were performed at 4°C in the presence of complete protease inhibitor cocktail (Merck, Darmstadt, Germany). Uniformly labelled The PRD of Tau, Tau(165-245), was expressed in E. coli using pET15b vector without any Tag. Purification included a first step of heating at 75°C for 15 min followed by cation exchange chromatography in sodium phosphate buffer pH6.5 (Hitrap SP sepharose FF, 5 mL; GE Healthcare, Little Chalfont, UK). Tau(165-245) was finally buffer exchanged against ammonium bicarbonate (Hiload 16/60 desalting column; GE Healthcare) for lyophilization.
CLAP(334-376) and Tau(210-240) peptides were synthesized via solid-phase synthesis (Genecust, Ellange, Luxembourg). After resin cleavage, peptides were purified by reverse-phase HPLC. The purity of the synthesized peptides were > 95%. The molecular weight of each peptide was confirmed by mass spectrometry. CLAP(334-376) and Tau (210-240) peptide sequences are QLKRGPPVPPPPKHT PSKEVKQEQILSLFEDTFVPEISVTTPS and SRTPSL PTPPTREPKKVAVVRTPPKSPSSAK, respectively, with SH3 recognition motifs underlined and the consensus residues in bold.
cDNA encoding CLAP(334-376) peptide was cloned into the pETNKI-HisSUMO3-LIC-Kan vector following a ligation-independent cloning procedure [36] . The expressed His 6 -SUMO CLAP(334-376) protein was purified using a nickel affinity chromatography column and then incubated with SENP2 protease in the presence of 2 mM DTT at 4°C overnight. The protein sample was buffer exchanged using a PD-10 column (G25 resin, cutoff of 7 kDa; GE Healthcare) against 50 mM sodium phosphate pH 7.3, 30 mM NaCl, 3 mM DTT, and then loaded on a nickel affinity chromatography column. The cleaved peptide was then recovered in the flow-through.
NMR spectroscopy
The NMR experiments were recorded at 20°C on Bruker 600-MHz (NMR assignment) or 900-MHz (titration experiments and BIN1 isoforms HSQC spectra) spectrometers both equipped with a triple-resonance cryogenic probe. NMR measurements were performed in 50 mM sodium phosphate buffer, pH 7. 
where Δd obs is the average weight of the chemical shifts in the free and bound states and Δd max is the maximum shift change on saturation. K d is the dissociation constant, a and b are the total peptide and SH3 concentrations respectively. K d calculated based on chemical shift perturbations of seven distinct resonances were averaged. In the competition experiments, the Tau(210-240) peptide was added to the preformed BIN1-SH3 domain-CLAP(334-376) complex yielding a final molar ratio of 1 : 8 : 8 and to the BIN1Iso1 at a molar ratio of 1 : 8. This ratio was chosen as it corresponds to near saturation during titration of BIN1-SH3 domain by both CLAP(334-376) and Tau(210-240) peptides.
Isothermal titration calorimetry (ITC)
Isothermal titration calorimetry experiments were performed at 25°C using a MicroCal iTC200 system (GE healthcare). BIN1-SH3 domain, Tau(210-240) and CLAP(334-376) peptide samples were dialysed in 50 mM sodium phosphate buffer, pH 7.3, 30 mM NaCl, 3 mM DTT. For Tau(210-240)/ CLAP(334-376)-SH3 domain-binding experiments, concentrations used in ITC measurement were 200 lM BIN1-SH3 domain in the reaction cell and 3 mM Tau(210-240) or 3 mM CLAP(334-376) peptide in the injection syringe. A control experiment was performed to measure heats of dilution by titrating Tau(210-240) or CLAP(334-376) peptides into buffer solution. The dilution contribution was subtracted from raw titration data. All data were analysed with MICROCAL Origin 7.0 using one site curve-fitting model.
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